Both BC and MET treatments repressed growth of MMQ xenograft tumours, and slightly shrank GH3 tumours; combined BC + MET further shrank both MMQ and GH3 xenograft tumours to more than 40% (Figure 5). The gene discussed is MET; the disease is breast cancer.